Organigram Shareholders Approve C$124.6 Million Investment from BAT, Appoint Karina Gehring to Board of Directors

TORONTO — At Organigram Holdings Inc.’s annual general and special meeting held on January 18, 2024, an ordinary resolution approving the previously announced C$124.6 million follow-on strategic equity investment by the Investor in the Company, was approved by the affirmative vote of 96.169% of the votes represented at the Meeting (or 86.926% of the voted represented at the Meeting excluding the votes attached to the common shares held by the Investor in accordance with Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions and the rules of the Toronto Stock Exchange).

Subject to the satisfaction or waiver of the other conditions to closing contained in the subscription agreement with the Investor dated November 5, 2023, as amended on December 20, 2023, the closing of the first tranche of the Investment is expected to close on or around January 23, 2024.

In addition, a special resolution approving the amendment of the Company’s articles to create a new class of Class A preferred shares to be issued by the Company to the Investor in the Investment was approved by the affirmative vote of 92.139% of the votes represented at the Meeting.

Following receipt of the necessary Shareholder approval, the Company filed articles of amendment to create the new class of Class A Preferred Shares. A copy of the articles of amendment will be available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The Class A Preferred Shares will not be listed for trading on the TSX or on any other stock exchange.

Further details relating to the Investment can be found in the press release issued by the Company on November 6, 2023 and the Circular.

Karina Gehring appointment

In addition, the company announced the appointment of Karina Gehring to the Organigram Board of Directors.

“We are thrilled to welcome Karina to our Board of Directors. Her extensive expertise in marketing and brand management combined with her ongoing experience with BAT will be a tremendous asset to our Board,” said Peter Amirault, Board Chair, Organigram.

Karina is one of two directors (including Simon Ashton) designated by BT DE Investments Inc., a wholly owned subsidiary of British American Tobacco plc (“BAT”), as nominees to the Company’s Board. Bringing over 25 years of experience in marketing and trade at BAT, Mrs. Gehring is a seasoned executive proficient in commercial delivery, brand management, strategy, consumer insights and key account management. Leading diverse teams, she has played a pivotal role in transformative initiatives across Europe and Canada. Mrs. Gehring has successfully executed full portfolio brand repositioning, deepened BAT’s consumer understanding to foster connections beyond surface insights and introduced innovative key account management programs.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc. a licensed producer of cannabis, cannabis-derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include changes to market conditions, consumer preferences and regulatory climate, and factors and risks as disclosed in the Circular, and the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. Such assumptions include, without limitation, that all conditions to the closing of the Investment will be satisfied, that the Investment will be completed on the terms set forth in the Subscription Agreement, and that all three tranches of the Investment will close. The forward-looking information included in this news release is provided as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.